Literature DB >> 26057322

Lower Dose Infliximab for Ulcerative Colitis: How Low Can We Go and How Much Can be Saved?

George P Christophi1, Matthew A Ciorba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26057322      PMCID： PMC4741379          DOI： 10.1097/MCG.0000000000000352

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


× No keyword cloud information.
  9 in total

1.  Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study.

Authors:  Monica Cesarini; Konstantinos Katsanos; Konstantinos Papamichael; Pierre Ellul; Peter L Lakatos; Flavio Caprioli; Uri Kopylov; Epameinondas Tsianos; Gerassimos J Mantzaris; Shomron Ben-Horin; Silvio Danese; Gionata Fiorino
Journal:  Dig Liver Dis       Date:  2013-11-15       Impact factor: 4.088

2.  Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Authors:  Adedigbo A Fasanmade; Omoniyi J Adedokun; Joyce Ford; Danika Hernandez; Jewel Johanns; Chuanpu Hu; Hugh M Davis; Honghui Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

3.  Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis.

Authors:  Xue-Liang Jiang; Hui-Fei Cui; Jing Gao; Hua Fan
Journal:  J Clin Gastroenterol       Date:  2015-08       Impact factor: 3.062

4.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

5.  Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis.

Authors:  Victoria Ung; Nguyen Xuan Thanh; Karen Wong; Karen I Kroeker; Thomas Lee; Haili Wang; Arto Ohinmaa; Philip Jacobs; Richard N Fedorak
Journal:  Clin Gastroenterol Hepatol       Date:  2014-03-24       Impact factor: 11.382

6.  Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.

Authors:  Bente Glintborg; Bjorn Gudbjornsson; Niels Steen Krogh; Emina Omerovic; Natalia Manilo; Mette Holland-Fischer; Hanne M Lindegaard; Anne Gitte Loft; Henrik Nordin; Laura Johnsen; Sussi Flejsborg Oeftiger; Annette Hansen; Claus Rasmussen; Gerdur Grondal; Arni Jon Geirsson; Merete Lund Hetland
Journal:  Rheumatology (Oxford)       Date:  2014-06-17       Impact factor: 7.580

7.  Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Authors:  Omoniyi J Adedokun; William J Sandborn; Brian G Feagan; Paul Rutgeerts; Zhenhua Xu; Colleen W Marano; Jewel Johanns; Honghui Zhou; Hugh M Davis; Freddy Cornillie; Walter Reinisch
Journal:  Gastroenterology       Date:  2014-08-28       Impact factor: 22.682

Review 8.  A porous defense: the leaky epithelial barrier in intestinal disease.

Authors:  Daniel R Clayburgh; Le Shen; Jerrold R Turner
Journal:  Lab Invest       Date:  2004-03       Impact factor: 5.662

9.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.

Authors:  C H Seow; A Newman; S P Irwin; A H Steinhart; M S Silverberg; G R Greenberg
Journal:  Gut       Date:  2010-01       Impact factor: 23.059
  9 in total
  1 in total

Review 1.  Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach.

Authors:  George P Christophi; Arvind Rengarajan; Matthew A Ciorba
Journal:  Clin Exp Gastroenterol       Date:  2016-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.